Cargando…

Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study

SUMMARY: A randomized placebo-controlled trial was conducted to examine the effect of daily oral 1 mg minodronate on vertebral fractures in 704 postmenopausal women with established osteoporosis for 24 months. Minodronate treatment reduced vertebral fractures by 59% without serious adverse events. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumoto, T., Hagino, H., Shiraki, M., Fukunaga, M., Nakano, T., Takaoka, K., Morii, H., Ohashi, Y., Nakamura, T.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2008
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2708326/ https://www.ncbi.nlm.nih.gov/pubmed/19101754 http://dx.doi.org/10.1007/s00198-008-0816-7

Ejemplares similares

Three years of treatment with minodronate in patients with postmenopausal osteoporosis
por: Hagino, Hiroshi, et al.
Publicado: (2011)

Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis
por: Okazaki, R., et al.
Publicado: (2011)

Minodronate for the treatment of osteoporosis
por: Ohishi, Tsuyoshi, et al.
Publicado: (2018)

Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene
por: Ohta, Hiroaki, et al.
Publicado: (2023)

Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
por: Nakamura, T., et al.
Publicado: (2016)

Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene
por: Toda, Aska, et al.
Publicado: (2017)

Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis
por: Hagino, Hiroshi, et al.
Publicado: (2012)

The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis
por: Hasegawa, Eriko, et al.
Publicado: (2018)

The effects of minodronate and activated vitamin D on bone mineral density and muscle mass in postmenopausal women with osteoporosis
por: Fujimoto, Kazuki, et al.
Publicado: (2018)

Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
por: Kobayashi, Masaki, et al.
Publicado: (2020)

A review of minodronic acid hydrate for the treatment of osteoporosis
por: Tanishima, Shinji, et al.
Publicado: (2013)

Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis
por: Liu, Qingshan, et al.
Publicado: (2020)

Influence on the bone mineral density and bone metabolism marker after the interruption and reinitiation of monthly minodronate therapy in postmenopausal women with osteoporosis
por: Okimoto, Nobukazu, et al.
Publicado: (2018)

Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
por: Nakamura, Toshitaka, et al.
Publicado: (2014)

Utility of monthly minodronate for osteoporosis after gastrectomy: Prospective multicenter randomized controlled trials
por: Hirota, Masashi, et al.
Publicado: (2021)

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
por: Sugimoto, T., et al.
Publicado: (2019)

Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary
por: Orimo, Hajime, et al.
Publicado: (2012)

Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study
por: Sakai, A., et al.
Publicado: (2014)

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2010)

Erratum to: Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study
por: Sakai, A., et al.
Publicado: (2014)

Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women
por: El Maghraoui, Abdellah, et al.
Publicado: (2014)

Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study
por: Suzuki, Takako, et al.
Publicado: (2019)

Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis
por: Urushihara, Hisashi, et al.
Publicado: (2014)

Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study
por: Tanaka, Mizue, et al.
Publicado: (2017)

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
por: Keaveny, Tony M, et al.
Publicado: (2014)

Thoracolumbar kyphosis in postmenopausal osteoporosis patients without vertebral compression fractures
por: Guo, Rui, et al.
Publicado: (2022)

Drug-induced hypersensitivity syndrome caused by minodronic acid hydrate
por: Muto, Yutaka, et al.
Publicado: (2021)

Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis
por: Sone, Teruki, et al.
Publicado: (2017)

Risedronate’s Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis
por: Gates, Brian J., et al.
Publicado: (2012)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
por: Sugimoto, T., et al.
Publicado: (2014)

Postmenopausal Osteoporosis
por: Kamel, Hosem K.
Publicado: (2006)

24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk
por: Sugimoto, Toshitsugu, et al.
Publicado: (2017)

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
por: Watts, N. B., et al.
Publicado: (2011)

Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis
por: Roux, C, et al.
Publicado: (2008)

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis
por: Nakamura, T., et al.
Publicado: (2015)

Validation of an osteoporosis self-assessment tool to identify primary osteoporosis and new osteoporotic vertebral fractures in postmenopausal Chinese women in Beijing
por: Yang, Yong, et al.
Publicado: (2013)

Botanicals in Postmenopausal Osteoporosis
por: Słupski, Wojciech, et al.
Publicado: (2021)

Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures
por: Iwamoto, Jun, et al.
Publicado: (2009)

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis
por: Meunier, P. J., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_6hg7515prldrnrvoppr3128d13